Form 13-F position report

IGM BIOSCIENCES INC COM

Reported by VANGUARD GROUP INC

IGMS CUSIP 449585108 Manager CIK 0000102909

Reported 409,803 shares, up 5,702 (1.4%) from the prior quarter.

Reported value 10.0%; share count 1.4% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2021
Shares 409,803 Quarter-end amount reported
Reported value $34,096,000 Fair value at quarter end
Consecutive quarters held 8 Through Q2 2021

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-03-31 30989000
2021-06-30 34096000
2021-09-30 27131000
2021-12-31 12173000
2022-03-31 22188000
2022-06-30 9213000
2022-09-30 11824000
2022-12-31 9817611
2023-03-31 7974174
2023-06-30 6435968
2023-09-30 7515058
2023-12-31 7455308
2024-03-31 8237800
2024-06-30 6036127
2024-09-30 14723908
2024-12-31 5476698
2025-03-31 1006905
2025-06-30 859213
2025-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

19 quarters
Quarterly reported position history for IGM BIOSCIENCES INC COM held by VANGUARD GROUP INC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2025 Reduced 0 -767,154 (-100.0%) 0 $0 2025-11-07
Q2 2025 Reduced 767,154 -108,415 (-12.4%) < 0.01% $859,213 2025-08-11
Q1 2025 Reduced 875,569 -20,781 (-2.3%) < 0.01% $1,006,905 2025-05-09
Q4 2024 Added 896,350 +6,150 (0.7%) < 0.01% $5,476,698 2025-02-11
Q3 2024 Added 890,200 +11,579 (1.3%) < 0.01% $14,723,908 2024-11-13
Q2 2024 Added 878,621 +24,963 (2.9%) < 0.01% $6,036,127 2024-08-13
Q1 2024 Reduced 853,658 -43,491 (-4.8%) < 0.01% $8,237,800 2024-05-10
Q4 2023 Reduced 897,149 -2,858 (-0.3%) < 0.01% $7,455,308 2024-02-14
Q3 2023 Added 900,007 +202,719 (29.1%) < 0.01% $7,515,058 2023-11-14
Q2 2023 Added 697,288 +116,926 (20.1%) < 0.01% $6,435,968 2023-08-14
Q1 2023 Added 580,362 +3,195 (0.6%) < 0.01% $7,974,174 2023-05-15
Q4 2022 Added 577,167 +57,190 (11.0%) < 0.01% $9,817,611 2023-02-10
Q3 2022 Added 519,977 +9,044 (1.8%) < 0.01% $11,824,000 2022-11-14
Q2 2022 Reduced 510,933 -319,144 (-38.4%) < 0.01% $9,213,000 2022-08-12
Q1 2022 Added 830,077 +415,028 (100.0%) < 0.01% $22,188,000 2022-05-13
Q4 2021 Added 415,049 +2,490 (0.6%) < 0.01% $12,173,000 2022-02-14
Q3 2021 Added 412,559 +2,756 (0.7%) < 0.01% $27,131,000 2021-11-12
Q2 2021 Added 409,803 +5,702 (1.4%) < 0.01% $34,096,000 2021-08-13
Q1 2021 Reduced 404,101 -36,830 (-8.4%) < 0.01% $30,989,000 2021-05-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

128 managers reported IGM BIOSCIENCES INC COM for Q2 2021.

Managers reporting IGM BIOSCIENCES INC COM in Q2 2021.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Redmile Group LLC Unchanged 3,425,455 0 4.22% $284,998,000 8 qtrs
BAKER BROS ADVISORS LP Unchanged 3,156,102 0 1.15% $262,588,000 8 qtrs
PRICE T ROWE ASSOCIATES INC MD Added 1,986,071 +189,760 0.02% $165,241,000 8 qtrs
Artal Group S A Reduced 1,100,000 -25,000 1.86% $91,520,000 4 qtrs
ALKEON CAPITAL MANAGEMENT LLC Reduced 1,051,429 -2,123 0.13% $87,479,000 6 qtrs
Woodline Partners LP Added 745,393 +314,710 1.16% $62,017,000 4 qtrs
BlackRock Inc Reduced 632,801 -106,244 < 0.01% $52,650,000 8 qtrs
STATE STREET CORPORATION Reduced 586,838 -100,377 < 0.01% $48,825,000 7 qtrs
PICTET ASSET MANAGEMENT LTD Added 439,297 +70,034 0.04% $36,550,000 6 qtrs
The Goldman Sachs Group Inc Reduced 422,883 -317,427 < 0.01% $35,184,000 5 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2021
Filed
August 13, 2021
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
16,387
None
393,416

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.